Better Health for All

Formycon AG's core business is the development and commercialization of biosimilars, which are follow-on versions of expensive biopharmaceutical drugs. This means 100% of its product portfolio, including candidates like FYB201, FYB202, FYB203, and FYB206, is dedicated to providing more affordable and accessible treatments for serious conditions such as diabetic retinopathy, macular degeneration, and diseases in ophthalmology, immunology, and immuno-oncology.

There is no evidence of any products with negative health outcomes. The company's R&D expenses in FY2023 were €9.2 million, representing 11.84% of its €77.7 million revenue, all directed towards health improvement. Formycon actively works to improve price accessibility, with biosimilar prices in the US noted to be at European levels. Its FYB201/BioUcenta™ biosimilar is specifically intended to address prohibitive costs and limited availability in Sub-Saharan Africa, aiming to provide equitable access for millions, particularly those with diabetes complications. FYB201 is currently available in 21 countries. The company also engages in patent settlements, such as with J&J for FYB201, and navigates litigation to bring its biosimilars to market, demonstrating an approach to patents that facilitates global health access. A Phase III trial for FYB206 was waived due to sufficient data from Phase I, potentially accelerating access.

Fair Money & Economic Opportunity

FORMYCON AG is a biosimilar developer, not a financial institution.

The company's core business involves the research, development, and commercialization of biosimilar drugs. The provided articles detail the company's financial performance, regulatory approvals for its biosimilar products, and a corporate bond issuance for investors. There is no evidence in the articles to suggest that FORMYCON AG offers lending, deposit, or other financial services to consumers, nor does it engage in activities related to financial inclusion, fair lending, or wealth building for underserved populations. Consequently, all KPIs under the 'Fair Money & Economic Opportunity' value are not applicable to the company's operations.

Honest & Fair Business

Formycon has implemented a formal whistleblower tool that allows for confidential and anonymous reporting of potential violations.

This tool complies with high standards for protecting identity and information security, and the company commits to handling allegations appropriately, without bias, and taking corrective measures. For financial reporting, KPMG AG Wirtschaftsprüfungsgesellschaft provided unqualified audit opinions for the consolidated financial statements for both fiscal years 2023 and 2024. The company has had zero financial restatements in the past five years. Regarding board independence, two Supervisory Board members, Wolfgang Essler and Klaus Röhrig, recused themselves from a vote on a loan agreement in 2024 due to potential conflicts of interest, though no other conflicts were reported by board members. The company has stringent guidelines for all employees on corruption and bribery, and a Code of Conduct that explicitly prohibits bribery, corruption, and undue advantage, with guidelines for gifts and benefits, emphasizing transparency and documentation. However, there is no evidence of regular training or risk assessments for this policy.

Kind to Animals

Formycon has an animal welfare policy based on the 3R principle (Replace, Reduce, Refine), which states that animal testing is only conducted when legally mandated or when results cannot be obtained by alternative methods.

The company prioritizes replacing animal testing with alternative methods, such as in vitro, ex vivo testing, or computer modeling, wherever feasible. All employees and business partners involved in animal testing must be properly trained and qualified. Formycon does not have its own animal-related operations, nor does it source animal-derived ingredients, eggs, meat, or dairy products. Therefore, KPIs related to humane certifications, ethical input substitution, cage-free sourcing, animal agriculture ethics, cruelty-free certification, and wildlife conservation impact are not applicable to its business model.

No War, No Weapons

The company develops biosimilar drugs, not arms, indicating no defense or arms-related activities in its core business.

Its biosimilars are intended for medical use and are not described as dual-use technologies, meaning no dual-use products are developed or sold. Furthermore, the company is not involved in the development or sale of weapons, confirming zero exposure to controversial weapons. Regarding conflict minerals, the company identified that the only 3TG in its products was cassiterite (tin) in electrical components of snow and ice control equipment. It contacted 98 direct suppliers for electrical components in the first six months of 2024, with a 75.5% response rate. Approximately 63.5% of responding suppliers indicated no 3TG from Covered Countries or recycled/scrap, while 18.9% indicated 3TG may have originated in a Covered Country. The company conducts a Reasonable Country of Origin Inquiry (RCOI) annually. Its due diligence measures are designed to conform in all material respects to the OECD Guidance. The company could not conclusively determine that they had no reason to believe that 3TG necessary for the functionality or production of their products may have originated from a Covered Country during 2024.

Planet-Friendly Business

The provided articles indicate a lack of publicly available quantitative data for all relevant environmental performance KPIs. While Formycon AG states a commitment to sustainability, ESG management, and reporting in accordance with the CSRD Directive, and has an environmental policy, no specific numerical data for carbon emissions, renewable energy use, water consumption, waste diversion, or other key environmental metrics are disclosed.

The company has been a member of the UN Global Compact since 2019.

Respect for Cultures & Communities

The provided articles primarily detail Formycon AG's internal Diversity, Equity, and Inclusion (DE&I) policies, codes of conduct, and general social responsibility strategy, focusing on employee diversity, well-being, and compliance with regulations like the General Equal Treatment Act (AGG) and UN Global Compact. While the company employs over 240 people from 33 nations and reports on gender representation in management,

there is no specific quantitative data or concrete actions related to direct engagement with local or indigenous communities, cultural preservation, local procurement, community-specific grievance mechanisms, or cultural impact assessments. Consequently, no evidence is available to score any of the KPIs for 'Respect for Cultures & Communities'.

Safe & Smart Tech

The company has no documented incidents of unauthorized data use. It states that the protection and security of personal and operational data are assured, with retention and deletion obligations observed.

Users, specifically shareholders, are afforded rights under GDPR including access, rectification, erasure, restriction of processing, data portability, and objection. The company explicitly states compliance with the General Data Protection Regulation (GDPR) and the German Federal Data Protection Act (Bundesdatenschutzgesetz). Data processing for shareholder rights is based on legal obligations under GDPR and AktG, with data recipients explicitly defined. Data minimization is evidenced by the processing of only necessary personal data for specific purposes, with retention periods generally up to three years after the general meeting, or a maximum of twelve months if a shareholder is no longer a shareholder, subject to legal proceedings.